Introduction
============

The influence of mesenchymal stem/stromal cells (MSCs) and the tumor microenvironment (TME) is now widely appreciated in cancer [@B1], [@B2]. However, distinct MSCs in the TME can come from different origins and exhibit a diversity of anticancer properties. Recently, increasing clinical trials have been performed to study the anticancer properties of MSCs. Currently, only MSCs originating from human tissue can be used in the clinic. In this review, we therefore mainly focus on the role of human-derived normal MSCs in anticancer therapies. We first discuss the use of different MSCs in the therapies for various cancers. We then focus on the anticancer mechanism and clinical application of these MSCs.

MSCs in anticancer therapies
============================

Many studies have reported pro- or anti-cancer effects of MSCs on the progression of primary and metastatic tumors. These contradictory results could be associated with differences in the MSCs source used, the type of tumor model and the method of administration or other unknown factors. Growing evidence showed that MSCs can migrate not only to primary tumor sites but also to pre-metastatic sites [@B3]-[@B5].

1. Blood cancers {#Section1}
----------------

MSCs of the bone marrow (BM), which we refer to here as BM-MSCs, support primary acute lymphoblastic leukemia (ALL) viability and also protect ALL cells (Reh cell line) from drug-induced apoptosis through an effect on cell cycle arrest via p21 down-regulation [@B6]. Another report also showed that BM-MSCs can rescue human B-ALL cells from apoptosis. The MSCs of umbilical cord/cord blood (UC-MSCs) inhibit the apoptosis of T-ALL cell line (Jurkat cells) [@B7]. Another study showed that UC-MSCs inhibited the proliferation of Jurkat cells, but did not induce apoptosis [@B8]. In contrast MSCs of adipose tissue (AT-MSCs) do not inhibit the proliferation of Jurkat cells [@B9]. Our study showed that UC-MSCs suppressed proliferation and promoted apoptosis, differentiation, and drug sensitivity of Jurkat cells [@B10]. We also observed that UC-MSCs can inhibit the growth and induce the apoptosis of tyrosine kinase inhibitor-resistant Philadelphia-positive ALL (unpublished data).

BM-MSCs from unrelated donors have been shown to support the phenotype of a leukemia stem cell derived from AML in a largely quiescent state in a long-term *in vitro* culture system. AT-MSCs protect acute promyelocytic leukemia (APL) cells from apoptosis induced by serum starvation or by doxorubicin [@B11]. The viability and activity of neutrophils differentiated from APL cell line (HL-60) were improved when HL-60 cells were cultured with AT-MSCs. However, UC-MSCs can inhibit the proliferation of K562 cell line and increase the cytotoxic effect of doxorubicin without induction of drug resistance [@B12]. UC-MSCs can induce the apoptotic and proliferative effects of Jurkat cells, HL-60 and K562 cells [@B13]. Another study showed that UC-MSCs protect HL-60 from Ara-c-induced apoptosis.

BM-MSCs derived from healthy donors protect chronic lymphocytic leukemia (CLL) cell survival with similar capacities to MSCs derived from CLL [@B14]. Adipocytes have been reported to cause CLL cells to become resistant to dexamethasone by providing lipid factors [@B15].

BM-MSCs have been seen to exhibit modest effects on cocultured lymphoma cell survival. *In vivo*, intra-peritoneal injection of BM-MSCs significantly increases the overall survival of xenograft models in nude-SCID mice [@B16]. AT-MSCs inhibit the growth of EL4 murine T-cell lymphoma by altering cell-cycle progression and inducing apoptosis *in vitro*, and can migrate to tumor sites and inhibit tumor growth in tumor-bearing nude mice and prolong their survival time. UC-MSCs significantly inhibit the growth of Burkitt\'s lymphoma cell lines (Ramos, CRL 1596) and increase cell death [@B17].

BM-MSCs support the growth of multiple myeloma (MM) cells. Both UC-MSCs and AT-MSCs inhibit MM cell growth and clonogenicity *in vitro* compare to BM-MSCs [@B18]. When RPMI-8226 MM cells were injected with UC-MSCs into mice, smaller subcutaneous tumormasses were formed, but delayed tumor burden growing was observed as the peritumoral injections of the same MSC subtype. Finally, both microarrays and ELISA revealed different expression of several genes and soluble factors in UC-MSCs as compared to other MSCs. The study also found that the soluble factors involved in MM biology, such as IL-6, IGF-1, and VEGF, were downregulated in UC-MSCs compared to BM-MSCs. The UC-MSCs significantly overexpressed genes involved in cell-to-cell communication, such as *RALA, MPG, SMAD-4, OGT, GRB-2*, and *MAP3K7*, while others that were functionally implicated in cell responses to inflammatory stimuli, such as *ELK-4, MCL-1, BCL-2,*and*MSH-2*, were significantly downregulated. Furthermore, other genes related to cell motility and chemotactic functions, such as *HGS, BCAR-1, PLOD-3,* and *PAFAH1B1*, were also overexpressed in UC-MSCs as compared to BM-MSCs. The intracellular formation of exosomes and microvesicles, as well as a variable modulation of genes involved in the secretion of dense granules and exocytosis of soluble molecules, such as *DNAJB-1, DNAJC-5, HPRT-1, HSPA1A, and BCL-2,*were also upregulated*.*Our recent study also showed that UC-MSCs can suppress proliferation and induce apoptosis in KM3 cells by downregulating IL-6R expression and inhibiting NF-κB activity [@B19].

2. Breast cancers {#Section2}
-----------------

BM-MSCs promote the proliferation of mouse breast cancer cell line 4T1 and human breast cancer cell line SUM1315 [@B20]. BM-MSCs promote the production of lysyl oxidase from breast carcinoma cells, which can promote the metastasis of breast cancer (MDAMB-231 and MCF7/Ras). A series of experiments demonstrated that adipocytes could induce both replicative potential and evasion of apoptosis in breast cancer cells [@B21]. UC-MSCs significantly inhibit the proliferation of breast cancer cell line MDA-MB-231 [@B22]. They also reduce lung metastasis and inhibit the growth of breast cancer cell line MDA-MB-231 by inducing apoptosis *in vitro* and *in vivo*. However, other reports showed that UC-MSCs promote proliferation and migration in breast cancer cell lines MCF-7, MDA-MB-231 and MCF-7 through activation of the ERK pathway and autocrine IL-8 and IL-6 signaling [@B23].

3. Cancers of the digestive system {#Section3}
----------------------------------

BM-MSCs can significantly promote the proliferation of hepatocellular carcinoma cell lines with high metastatic potential (MHCC97-H) and low-metastatic potential (MHCC97-L) [@B24]. They also promote the metastasis of human hepatic cancer cell lines (SMMC7721, SK-Hep1 and Hep-3B). Another report showed that BM-MSCs promote the proliferation of metastatic hepatic cancer cell line MHCC97-H *in vivo* and *vitro*, but inhibit its metastasis [@B25]. AT-MSCs efficiently inhibit human hepatic cancer cell line (HepG2, Huh7, SMMC7721, and Bel7402) proliferation and division, and induce cell death through the downregulation of Akt signaling [@B26]. UC-MSCs exert a suppressive effect on the growth of a hepatic cancer cell line (Huh7-DsRed2 cells), and have a tumor-specific, antiproliferative effect that is not observed with normal human hepatocyte cells or patient-derived matched normal tissues [@B27]. UC-MSCs also inhibit the malignant phenotype of human cholangiocarcinoma cell line HCCC-9810.

BM-MSCs promote the progression of colorectal cancer cell lines (HCT-8/E11, HCT 116, SW480, HT-29, LoVo, T84 CRC and ANC-1) [@B28]. MSCs derived from fetal and adult BM alone or together with human colon cancer cell line SW480 were transplanted subcutaneously into BALB/c-nu/nu mice to observe the outgrowth of tumors. The results showed that both types of MSCs promoted tumor growth *in vivo*. However, AT-MSCs significantly suppressed the proliferation of colorectal adenocarcinoma (HT-29*) in vitro* and in mice xenografts. Other reports showed that AT-MSCs enhance the metastatic capacity of colon cancer cell lines (HCT116, LoVo cells, SW480, LS174T and CCD-18Co) in a colon cancer cell co-culture model [@B29]. AT-MSCs also promote the expression of the growth marker, proliferation cell nuclear antigen, but inhibit apoptosis markers and single-stranded DNA in the well- and poorly differentiated types of gastric adenocarcinoma cell lines (MKN28 and MKN45). UC-MSCs promote the proliferation of gastric epithelial cell lines (GES-1 and the SGC-7901) *in vitro* and *in vivo* [@B30]. They can also promote carcinoma growth and lymph node metastasis when co-injected with esophageal cancer cell lines (Eca109 and TE-1) in nude mice. However, artificial fusion of MSCs with esophageal carcinoma cell line EC9706 resulted in hybrids with declined cell growth, increased apoptosis and suppressed tumorigenicity [@B31]. UC-MSCs promote the proliferation of mouse pancreatic cancer cell line Pan02 *in vivo*, however, MSCs producing IL-15 eradicate established pancreatic tumors in syngeneic mice [@B32].

4. Cancers of the respiratory system {#Section4}
------------------------------------

AT-MSCs stimulate adhesion and proliferation of human lung adenocarcinoma cell line A549 *in vivo* and *in vitro* [@B33]. They also promote the proliferation of large cell lung cancer cell line H460, and co-injection of MSCs with H460 promotes tumor growth *in vivo* along with a reduction in apoptotic cell death. However, another study showed that AT-MSCs do not affect the proliferation of lung adenocarcinoma cell line (A549) *in vitro* or promote tumor growth *in vivo*. UC-MSCs can inhibit the proliferation of human bronchioloalveolar carcinoma cell lines (H358 or SW1573) [@B34].

5. Cancers of the urinary system {#Section5}
--------------------------------

BM-MSCs promote growth and angiogenesis of prostate cancer cell line DU145. AT-MSCs can inhibit the proliferation and induce the apoptosis of both androgen-responsive (LNCaP) and androgen-nonresponsive (PC3) human prostate cancer cells [@B35]. Another study showed that AT-MSCs increase cell viability of prostate tumor cell lines LNCaP and LNCaP-Bic, but no effect was observed for Du145 or PC3. UC-MSCs induce apoptosis in prostate cancer cell line PC-3 and attenuate bladder tumor cell growth *in vitro* and *in vivo* [@B36]. However, BM-MSCs do not inhibit the proliferation of renal cell carcinoma cell lines (RCC42 and RCC52), but increase their migratory ability and invasiveness *in vitro* [@B37].

6. Gynecological cancers {#Section6}
------------------------

AT-MSCs have no effect on the proliferation of the cervical cancer HeLa cell line. They promote cell proliferation and invasion of human epithelial ovarian cancer cell lines (SKOV3, CAOV3, A2780 and ES2) [@B38]. Both AT-MSCs and BM-MSCs promote vascularization and growth of endometrial tumors [@B39]. UC-MSCs inhibit the growth of ovarian carcinoma cell line TOV-112D *in vitro* [@B40].

7. Cancers of the nervous system {#Section7}
--------------------------------

BM-MSCs suppress the growth of human primary glioma cells through inhibition of angiogenesis. AT-MSCs promote the proliferation of human glioma cell line U87MG. Co-injection of MSCs with U87MG promotes tumor growth *in vivo* and also induces a reduction in apoptotic cell death. AT-MSCs and UC-MSCs can efficiently induce apoptosis and differentiation in human glioma cell line U251 *in vitro* [@B41]. UC-MSCs have a significant cytotoxicity against malignant glioma cell line U87MG, and mixed-source MSCs have significantly higher cytotoxicity than UC-MSCs alone for glioma cell line C6. UC-MSCs also inhibit the growth of primary glioblastoma multiforme (GBM) cells and cause apoptosis both *in vitro* and *in vivo*; however, AT-MSCs promote GBM growth.

8. Other cancers {#Section8}
----------------

AT-MSCs promote migration and early metastasis of head/neck cancer cell lines Cal-27 and SCC-4 *in vitro* and in xenografts [@B42]. AT-MSCs inhibit the growth of human melanoma cell lines (A375SM and A375P) by inducing apoptosis and altering cell-cycle distribution *in vitro*. AT-MSCs also suppress tumor growth and migrate to tumor tissues in tumor-bearing athymic mice [@B43]. AT-MSCs have no growth-inhibitory effect on human medulloblastoma cell line D283-MED, however, MSCs transfected with neurotrophin-3 significantly inhibit the growth of D283-MED [@B44].

Altogether, the MSCs derived from different tissues show great diversity in their anticancer properties. It seems that the UC-MSCs are ideal cells for anticancer therapies (Table [1](#T1){ref-type="table"}). While complex interactions between these different cell types reshape the surrounding extracellular matrix as cancer progresses, neoplastic and stromal cells also undergo constant changes.

The mechanism of MSCs in anticancer therapies
=============================================

In recent years, growing literature has focused on the potential role of MSCs in malignancies. Because many oncological therapies employ MSCs as cellular vehicles, it is necessary to shed light on the mechanism by which MSCs act on the different cells which constitute the tumor microenvironment in anticancer therapies (Fig [1](#F1){ref-type="fig"}).

1. MSCs change normal fibroblasts to tumor-associated fibroblasts {#Section1_1}
-----------------------------------------------------------------

The tumor stroma that includes many different types of extracellular matrix (ECM) and non-cancerous cells acts as an essential microenvironment for cancer cells. The major cellular constituents of the tumor stroma are fibroblasts that called as cancer-associated fibroblasts**(**CAFs). CAFs express α-smooth muscle actin (α-SMA), which is proposed to have strong contractility, and contribute to the stiffening and remodeling of the stromal ECM and also offering a right field for tumor cell invasion.

The surrounding normal tissues were invaded by cancer cells that is necessary for distant metathesis, and is started by the detachment of tumor cells from the primary tumor. Breakdown of the basement membrane around the tumor tissues, the loss of cell-cell adhesion and cell migration into the tumor stroma were required during this process. The EMT of the neighboring cancer cells through paracrine signaling by CAFs secrete soluble factors including THGF and TGF-β. CAFs can also secrete matrix-degrading enzymes, which indicates that control by CAFs is vitally important in anticancer therapies.

BM-MSCs promote the conversion of normal fibroblasts to CAF, which causes increased growth and invasion of prostate cancer cell lines (LNCap and C4-2) through TGFβ-1 *in vitro* and *in vivo* [@B45]. However, interruption with TGFβ-1 inhibitor SB431542 led to alteration of the MSC-induced CAF conversion and the prostate cancer cell growth and invasion was inhibited.

2. MSC transition into CAFs {#Section2_1}
---------------------------

CAFs as a major constituent of the tumor stroma support malignant cell growth and spreading. Recent study in mouse models of inflammation-induced gastric cancer suggested that at least 20% of CAFs originate from BM-MSCs.

When in direct contact with colon cancer cells, BM-MSCs differentiate into CAFs. BM-MSCs exposed to tumor-conditioned medium (MDAMB231, PANC-1 and U87) over a prolonged period of time assume a CAF-like myofibroblastic phenotype and promote tumor cell growth both *in vitro*and in an *in vivo*co-implantation model. However, BM-MSCs induced to differentiate into a myofibroblast-like phenotype using 5-azacytidine do not promote tumor cell growth [@B46]. Under long-term tumor conditioning *in vitro*, BM-MSCs can transition into CAFs and stimulate tumor growth through the paracrine production of secreted IL-6 *in vivo*. BM-MSCs transform into CAFs when cultured with certain cancers (human ovarian cancer TOV-112D; breast cancer MDA-MB-231), but no changes were observed when UC-MSCs were co-cultured in the same conditions [@B47]. The exosomes released by primary CLL cells and cell line MEC-1 can also induce BM-MSCs to transition into CAFs.

AT-MSCs and UC-MSCs are susceptible to CAF transition under certain conditions as well. The exosomes from breast cancer cells (MCF-7 and MDA-MB231) can convert AT-MSCs into myofibroblast-like cells [@B48]. The lysophosphatidic acid derived from human ovarian adenocarcinoma cell line OVCAR-3 stimulates differentiation of AT-MSCs into CAFs. The exosomes of gastric cancer (SGC7901, HGC27 and GES-1) also trigger UC-MSCs to CAFs through the TGF-β/Smad pathway.

Although CAFs derived from MSCs block the transition of MSCs into CAFs, they can also abolish their protumor effects. A recent study with customized cDNA microarrays to compare the gene expression profiles of stromal cells from primary tumor tissue, lymph node metastasis and BM obtained from breast cancer patients showed that only small differences were observed in the transcriptional profiles of fibroblasts from the primary tumor and lymph node, whereas greater differences were observed between BM stromal cells and the other two sites [@B49]. Another study showed that only normal, non-malignant mesenchymal progenitor cells and normal osteosarcoma-derived MSCs but not tumor cells could be cultured from primary human osteosarcoma samples when applying standard MSC culture techniques. An animal study showed that human cancer cells grafted to nu/nu mice can induce the formation of tumor stroma that has the typical smooth muscle actin-containing CAFs that seem to be of the host origin because they are not recognized by an antibody specific for human vimentin, as was also verified *in vitro*. These showed that the CAFs are not formed from cancer cells [@B50]. The depletion of CAFs leads to increased tumor invasion associated with decreased survival in transgenic mice with the ability to delete αSMA (+) myofibroblasts in pancreatic ductal adenocarcinoma; fewer myofibroblasts in these tumors also correlated with reduced survival in patients with invasive pancreatic adenocarcinoma [@B51]. CAFs are derived from both MSCs and local fibroblasts, which suggests that the primitive undifferentiated MSCs can be presented even in advanced cancers. Even within the same type of tumor, the heterogeneous populations of MSCs and CAFs may have different phenotypic characteristics. Taken together, these studies suggest that not all CAFs are malignant, and we should carefully identify and use them.

3. MSCs control the EMT {#Section3_1}
-----------------------

BM-MSCs have been shown to induce gastric cancer cell EMT and promote transwell and trans-endothelial migration *in vitro*, as well as remarkably increase tumor mass and liver metastasis *in vivo*. They also stimulate EMT of breast cancer cell lines (MDA-MB-231, T47D and SK-Br-3) [@B52]. BM-MSCs also induce EMT in human colorectal cancer cell lines (HCT116, LS180, COLO205, HT29 and SW480) through the expression of surface-bound TGF-β. AT-MSCs can promote the EMT of human breast cancer cell line MCF7 through paracrine and induced autocrine TGF-β [@B53]. Adipose MSCs can also induce EMT of lung cancer cells (H358). However, glioma stem cells from patients treated with the UC-MSCs revert the EMT by down regulating transcriptional activation of Sox2 and Twist1, which results in a decrease in the invasive ability of tumor cells. In the intracranial glioma stem cell-induced tumors of mice, treatment with UC-MSCs significantly reduces glioma stem cell-induced tumor volumes [@B54].

MSC-induced EMT of cancer cells contributes to the malignant characteristics of tumors, such as local invasion and distant metastasis. However, normal fibroblasts can also induce the EMT of tumor cells. EMT also regulates the stem cell-like characteristics of both malignant and normal cells [@B55]. The EMT program seems to be linked to the residence of cells in stem cell-like states in some epithelial tissues on the one hand, but on the other hand, they are also coopted by cancer cells which enable them to acquire cellular traits associated with high-grade malignancy. Therefore, two aspects of the EMT program are worthy of detailed examination.

4. Immune regulation {#Section4_1}
--------------------

The immunosuppressive property of MSCs is useful for anticancer therapies because they are capable of inhibiting the proliferation of all effector cells of the peripheral blood, such as NK cells, T cells, and B cells. The affected cells are inhibited not only in their proliferative capacity, but also in their cytolysis and antibody production *in vitro*and *in vivo*. This immunosuppression at a cellular level is widely considered to be the functional basis for the systemic effects of MSCs and involves several soluble factors, such as galectin-3, galectin-9, IL-10, indoleamine 2, 3-dioxgynease and HLA-G.

In an *in vitro*study of human gliomas, MSC-like pericytes similar to BM-MSCs displayed inhibitory functions on CD4^+^T cells through prostaglandin-E2 and HG. Recently, glioma pericytes were shown to switch from a tumor-suppressive phenotype to a tumor-promoting one in a xenograft model. The antiproliferative effect of MSCs also affects microglia cells by reducing the level of tumour necrosis factor-α [@B56]. MSCs isolated from tumors showed immunosuppressive properties and can downregulate the activating NK cell receptors and impair tumor lysis by NK cells *in vitro*[@B57]. Tumor-associated MSCs producing the immunosuppressive interleukin-10 were markedly increased in cervical cancer compared to normal BM-MSCs, which underpins the role of tumor-associated MSCs in establishing an immunosilenced, quiescent niche. Another report also showed an inhibitory effect of MSCs on various immune effector cells. These data suggest that the tumor-promoting effect of MSCs is due to suppression of immune effector cells. TAFs could also induce CD3/CD28-dependent activation of T cells and do not appear to inhibit these effector cells [@B58].

One caveat should be noted, however, among these publications, very few experimental designs aimed at a side-by-side comparison of tumor-derived MSCs with fibroblasts or MSCs from adjacent healthy tissue, umbilical cord/cord blood or normal adipose tissues. Without an adequate control population, whether the sole measurement of effector cell proliferation or receptor expression status can faithfully reproduce the conditions in the tumor is questionable.

5. MSCs replace host cells {#Section5_1}
--------------------------

Transdifferentiation and cell fusion are two explanations for cell replacement. Transdifferentiation means that MSCs can differentiate across lineage barriers into a diverse array of cell types. Cell fusion refers to fusion between MSCs and host cells, which can result in reprogramming of the host nucleus to express MSC-specific genes, which can then regulate the growth, apoptosis and metastasis of cancer cells.

Cell replacement was originally thought to be the major mechanism by which MSCs exert anticancer effects. BM-MSCs acquire epithelial characteristics through fusion with gastrointestinal epithelial cells *in vitro* and *in vivo* [@B59]. BM-MSCs co-cultured with glioma cell lines (U87 and U373) inhibit the proliferation of glioma cells but improve their movement. Another study observed that MSCs can fuse with glioma cells to form a functional and structural syncytium. BM-MSCs spontaneously form tumorigenic hybrids with non-small cell lung cancer cell lines (A549, H460, or SK-MES-1). Hybrids acquire increased motility and invasiveness and form more tumor spheres than the single cancer cells. In NOD/SCID mice, heterotypic hybrids exhibit enhanced tumorigenicity and reproduce the human tumor [@B60]. Fusion of BM-MSCs with SU3 glioma cells contributes to glioma neovascularization. AT-MSCs fuse with breast carcinoma cell lines (T47D) and the cancer cells express higher transcription levels of typical malignancy markers in co-cultures compared with single cultures [@B61].

It was found during co-culture that MDA-MB231 and UC-MSCs may adhere upon contact at a variable ratio from 1:1 to 9:1, and all the MDA-MB231 cells in this study shrank following contact with MSCs [@B61]. More specifically, two different interactions were observed. First, the MDA-MB231 cells shrank immediately upon adhesion and infusion of some substance from MSCs. Secondly, the MSCs internalized into MDA-MB231 to form a cell-in-cell structure, though the two cells separated after a short period. The separated MDA-MB231 cells shrank and died, while the separated MSCs went on to contact other MDA-MB231 cells and shrink them as well. The artificial fusion of UC-MSCs with esophageal cancer cell line EC9706 resulted in hybrids with decreased cell growth, increased apoptosis and suppressed tumorigenicity [@B31]. UC-MSCs can spontaneously fuse with lung cancer cell line H441 to form synkaryonic hybrids and reprogram the transcriptome of the lung cancer cells through FOXF1, which reduces their growth rate and tumorigenicity [@B62]. Another study showed that UC-MSCs can exchange membrane proteins and fuse with several tumor cell lines (breast carcinoma cell line MCF-7; Ovarian cancer cell lines NIH OVCAR-3 and SK-OV-3) and enhance the cancers\' cell growth. However, some researchers have raised doubts about these findings. In one relevant study, the authors performed double immunostaining of ataxic mouse cerebellum with MAB1287 (UC-MSC marker) and anti-GFAP (astrocyte marker), anti-NeuN (neuron marker) or calbindin (Purkinje cell marker) to display the differentiation of implanted UC-MSCs. The results demonstrated that MAB1287-positive cells rarely co-localized with GFAP, NeuN or calbindin, which implies little relation between the efficiency of UC-MSCs and cell replacement [@B63].

It should be noted that after transplantation, a large proportion of MSCs can be observed in capillaries within the liver, spleen, lung and other off-target tissues. The number of cells that enter the cancer site is far from being enough for tissue reengineering.

6. MSCs remodel the ECM {#Section6_1}
-----------------------

Remodeling of the ECM by stimulating epithelial cell transformation induces the migration, invasion, and metastasis of cancer cells. The production of proteolytic ECM affects focal adhesions at cell membranes, cellular cytoskeletal organization, integrin-mediated anchorage of cells, and the signal transduction regulating these structures.

ECM is composed by a complex mixture of components, including proteins, glycoproteins, proteoglycans and polysaccharides. MSCs contribute to formatting or remodeling the tumor stroma, which promotes or inhibits the progression of cancer through focal proteolysis that causes the release of bioactive fragments from ECM molecules, breaks cell-matrix interactions with integrins and receptors, and disrupts the ECM architecture. ECM derived from BM-MSCs increases the survival of prostate cancer cell lines (LNCaP and MDA-PCa-2b) in androgen-depleted conditions, and induces morphological changes and chemoresistance in LNCaP cells through the MEK1/2 or PI3K pathway. BM-MSCs promote the growth of colorectal carcinoma cell line HCT8 with different mutational conditions *in vitro* and *in vivo*. MSCs interacting with colorectal carcinoma cells facilitate three-dimensional spheroid formation through a dysfunctional E-cadherin system and secrecte type I collagen [@B64]. BM-MSCs inhibit the proliferation but increase the invasion of oral tongue tumor cell lines (HSC-3, SAS and DOK) through the secrection of type I collagen. UC-MSCs secrete dickkopf (DKK1) to arrest the growth of breast cancer cell line MDA-MB-231 by upregulating levels of PTEN [@B65].

7. Paracrine action {#Section7_1}
-------------------

Recently, researchers have focused increasing attention on the paracrine actions of MSCs. MSCs can secrete an extensive variety of growth factors, cytokines, and chemokines, including quantities of hepatocyte growth factor, monocyte chemotactic protein-1and stromal-derived factor-1, insulin-like growth factor-1, brain-derived neurotrophic factor, glial cell-derived neurotrophic factor vascular endothelial growth factor and interleukin-8. These released factors may promote or inhibit the growth and metastasis of cancer cells *in vitro* and *in vivo*. For example, BM-MSCs and UC-MSCs can inhibit cell cycle progression and induce senescence and differentiation of glioblastoma multiforme stem-like cell lines (NCH421k, NCH644, NIB26, and NIB50). By secrecting soluble NRG1, BM-MSCs promote the progression of colorectal cancer [@B28]. They also secrete insulin growth factor binding proteins to inhibit the growth of liver cancer cell line (Huh7-DsRed2) through reduced activation of IGF-1R/PI3K/Akt signaling [@B66]. BM-MSCs secrecte IL-6, which promotes growth of osteosarcoma cell line Saos-2 *in vitro*, and the proximal tibia of nude mice injected with MSCs combined with Saos-2 could also promote tumor growth and progression. No effect on cell proliferation was observed for breast cancer cell line MCF7 cultured with AT-MSCs, which secrecte TGF-β, but increased invasive and migratory capacities were observed [@B53]. UC-MSCs inhibit the proliferation of human erythromyeloblastoid leukaemic cell line K562 through the secretion of IL-6 and IL-8 [@B12]. UC-MSCs also secrete IL-2 and interferon-gamma, which inhibit the proliferation of malignant glioma cell line C6.

8. Cell-cell contact {#Section8_1}
--------------------

MSCs exist in a special microenvironment in which they can interplay with the host cells via gap junctions, tight junctions, adherens junctions and desmosomes to affect the proliferation, migration and differentiation of host cells.

The expression of connexin 43 (the major component of gap junction-mediated intercellular communication) increases in BM-MSCs co-cultured with multiple myeloma cell line RPMI8226, and the gap junction inhibitor 18a-GA inhibits the migration and adhension of RPMI8226 induced by MSCs [@B67]. BM-MSCs transfected with *TRAIL* combined with a gap junction inhibitor can enhance glioma cell death. Direct co-cultures of human glioblastoma cell lines (8-MGBA, 42-MG-BA and U-118 MG) with AT-MSCs transfected with herpes simplex virus-thymidine kinase and the prodrug ganciclovir (TK-MSC/GCV) resulted in a substantial decrease in viability *in vitro* through the formation of gap junctions between MSCs and glioblastoma cells; however, the inability of breast adenocarcinoma cell line MCF7 and cervical epitheloid carcinoma cell line HeLa to form gap junctions with MSCs renders these cells refractory to TK-MSC/GCV-mediated cytotoxicity [@B68]. The proliferation and vascular network formation of endothelial cells are decreased through the direct gap junction communication with UC-MSCs, possibly due to the secretion of cytokines and growth factors attributed to cell-to-cell contact [@B69]. UC-MSCs coculured with breast cancer cell line MDA-MB-231 can spontaneously generate hybrid/chimeric cell populations and induce expression of the GPI-anchored CD90 molecule in breast cancer cells, which can be partially blocked by a gap junction inhibitor *in vitro*and *in vivo*, leading to stimulation of breast cancer cell growth [@B70]. Our previous study showed that increased expression of CX43 on UC-MSCs promotes leukemia apoptosis [@B71].

Clinical applications of MSCs in anticancer therapies
=====================================================

MSCs are currently under investigation for a variety of clinical therapeutic trials. Despite constant doubt about the antitumor properties of MSCs, application of MSCs is a burgeoning strategy for cancer treatment in clinical settings

Some studies reviewed here have shown that MSCs can promote the growth of tumors. Nevertheless, some researchers have argued that malignant transformation is only a theoretical risk, and there is low probability of tumor formation after MSC transplantation [@B72]. A systematic review showed that tumorigenicity may occur only in patients suffering from ongoing or previous malignancy [@B73]. The safety and tolerability of autologous BM-MSCs with herpes simplex transduction has been studied in an ongoing phase I/II study (NCT02008539). The most frequent clinical use of MSCs thus far has been for blood disorders, especially graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation. MSC transplantation has been demonstrated to have therapeutic effects in some clinical pilot studies [@B74]. Twenty patients with hematologic malignancies received MSC transplantation together with allogeneic hematopoietic cell transfusion. The cotransplantation resulted in 80% overall survival and 60% progression-free survival. Similar treatments without MSC cotransplantation resulted in 44% overall survival and 38% progression-free survival. Serial MSC transfusions demonstrated an encouraging 78.1% 100-day survival rate, whereas patients who did not respond to the MSC infusions had 100-day survival of only 31%. The *ex vivo*culture of MSCs before transfusion decreases the overall survival of the patients, although phase I/II clinical trials have demonstrated the safety of the procedure. Another study of a very small number of cases also showed that co-transplantation of cultured MSCs *in vitro* could not only result in decreased survival, but also result in disease relapse [@B75]. Therefore, the co-transplatation of granulocyte-colony stimulating factor-mobilized BM could be a better way to treat cancers because of the higher MSC titer in the collection without the need for *ex vivo* culture [@B76], [@B77].

Currently, new clinical trials are recruiting patients to further explore the potential of MSCs in anticancer therapies (Table [2](#T2){ref-type="table"}). Based on the observed data and ongoing studies, MSC transfusion is a promising tool to improve the efficiency of cancer treatments.

Future clinical consideration
=============================

As described here, human-derived normal MSCs play important roles in anticancer therapies; however, UC-MSCs have produced better outcomes. Nevertheless, some challenges that include the available sources and convenience of obtaining MSCs, the quality control of *in vitro*-cultured MSCs, the appropriate cell passages, the optimum number of infusions, the optimum cell dose and the efficacy and safety of use remain to be discussed before large-scale clinical application of MSCs. Furthermore, and especially important, is the need to evaluate whether the rates of cancer relapse and infections increase when MSCs are used to treat or prevent diseases such as GVHD.

Acquiring MSCs from BM or adipose tissue involves an invasive and painful procedure. Human umbilical cord tissue seems to be the optimal source of adult multipotent stem cells for clinical application because MSCs from umbilical cord/cord blood are characterized by higher proliferation, faster self-renewal ability, more stable doubling time, lower immunogenicity, more feasible harvest and more effective anticancer properties than MSCs from BM or adipose tissues.

Many investigations have demonstrated that infusion of MSCs is safe and does not carry the risk of ectopic tissue formation or other severe adverse events. However, some preliminary studies also showed that MSC cultures can be infected with both cytomegalovirus and herpes simplex virus-1 *in vitro*. Even though MSCs of umbilical cord/cord blood are more primitive than MSCs of BM and adipose tissues, the safety of their use remains uncertain with the limited data thus far reported. Immunodeficient patients with ataxia telangiectasia developed a donor-derived brain tumor after transplantation of a mixture of fetally derived neural cells [@B78]. We are looking forward to obtaining more evidence of the safety and efficacy of MSCs as more and more clinical trials report their results.

One of the characteristics for MSCs is that possess a great propensity for expansion *in vitro*. Thus, passaged cells are extensively used in experimental and clinical practices, which may potentially lead with increasing transforming events to the establishment of a novel cell. MSCs within six passages are suggested for clinical applications because cells of increasing passages may also gradually lose the properties of early progenitors, such as the abilities of proliferation and differentiation. In addition, it is difficult to guarantee the quality of MSCs for physicians because malignant transformation as well as genomic mutations cannot be completely avoided in the complicated microenvironments in the body after implantation and long-term culture *in vitro*. Therefore, genetic testing of the donor, strict control of cell-handling procedures and long-term supervision is needed. Banks of cryopreserved/manufactured MSCs, such as cord blood banks, may serve to improve several issues regarding the application of MSCs to clinical practice, including the variability of donors, the time needed to obtain sufficient cells and the risk of contamination, and could provide a ready supply of MSCs for clinical use.

According to recent reports, the majority of patients in clinical trials thus far have received MSCs at dosages of 1-9×10^6^/kg. However, the optimum therapeutic cell dose has not been well established. The immunosuppressive effects of MSCs have been seen to increase in a dose-dependent manner *in vitro.* However, increased therapeutic effects are not guaranteed with increased MSC infusion. On the other hand, the donor MSCs are gradually eliminated from the recipient after infusion. Accordingly, several MSC infusions may be needed to develop immune tolerance in patients with severe immune disorders. MSCs administered at different ratios to cancer cells show different results. Therefore, further studies are warranted to define the optimum dose of MSCs, as well as the optimum number of infusions.

Enhancing the efficiency of delivering MSCs and cell homing could improve their therapeutic effects. It is necessary to improve approaches to promoting migration and longevity of MSCs in specific tissues. Bioengineering approaches and genetic modifications may provide opportunities to solve these problems in the future. Furthermore, at the present, it is very difficult to mimic human baseline conditions that are associated with the occurrence, development and prognosis of diseases. Therefore, laboratory disease models are in dire need of common standards.

Despite the ability of MSCs to differentiate into multiple cell lineages *in vitro*, recent evidence suggests that the fate of MSCs may be restricted in BM *in vivo*, with only the ability to replenish osteogenic lineages, such as the osteoblasts that form part of the endosteal niche. A recent report described how malignant myeloid cells profoundly reprogram the endosteal BM osteoblasts into a pro-inflammatory BM niche that supports LSCs while creating an inhospitable environment for normal HSCs. Indeed, human LSCs have been transplanted *in vivo* and been shown to home to the epiphyseal osteoblastic surface of the endosteum before later dispersion to perivascular niches in vessels near the endosteum and diaphysis. MSC-derived osteoblasts are more harbinger than host in haematopoiesis. However, the abnormal differentiation and location in the niche is more related to the growth of LSCs than to normal hematopoietic stem cells. Recent research showed that AML induces MSCs to differentiate into osteoblasts, increasing their number above normal levels; however, the number of osteoblasts normalized after removal of AML. Larger amounts of osteoblasts have also been observed in patients with AML, with osteoblast numbers higher during relapse than in remission. Gene expression and *in vitro* functions of MSCs from leukemia also change. Thus, we should pay attention to whether MSCs *in vivo* and *in vitro* can eliminate leukemia MSCs, re-educate the leukemia MSCs to act as normal MSCs, or induce osteoblasts to reduce to normal levels. Preliminary studies from our lab have shown that both the MSCs of umbilical cord blood and of normal BM co-cultured with leukemia MSCs can decrease the numbers of leukemia MSCs. The inhibition rate of leukemia MSCs was significantly higher with the MSCs of umbilical cord blood than with the MSCs of normal BM. The inhibition rate increased with the number of UC-MSCs used, but decreased with increasing numbers of MSCs from normal BM \[Fig [2](#F2){ref-type="fig"}\].

In addition to their primary effects, MSCs could be employed as carriers of multiple anticancer agents because they can track microscopic tumors and pathological lesions without incurring the risk of spreading tumor cells. Therefore, they could be used as a vehicle for anticancer drugs or tumor-suppressor genes when drug resistance occurs or systemic treatments fail. Because of their larger loading capacity, better durability and lower risk of spreading tumors, MSCs of the umbilical cord/cord blood can be considered as an ideal delivery vector for multiple anticancer agents.

Recently, two phenotypes of MSCs, called MSC1 and MSC2, have been isolated from a mixed population of MSCs using a completely novel approach, and the researchers found that MSC1s are pro-inflammatory while MSC2s are immunosuppressive in nature [@B79]. Researchers in the same group reported that MSC1s are anti-tumorigenic while MSC2s are pro-tumorigenic in nature [@B80]. The appropriate culture, isolation and identification of the MSC1 and MSC2 subpopulations may help resolve some of the surrounding controversies to advance the safe use of MSCs in anticancer therapies.

In summary, although controversy exists and cell-based therapy will not completely take the place of conventional therapeutic tools, researchers still hold the view that cancer therapy based on MSCs has a promising future. However, many problems still remain to be solved before clinical applications of MSCs can be more widely implemented. We believe that the era of the MSCs as a new clinical paradigm of anticancer therapies is upcoming.
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![Mechanism of mesenchymal stem cell action in anticancer therapies. The primary role of MSCs in anticancer therapies lies in their abilities to change normal fibroblasts into tumor-associated fibroblasts, transition into CAFs, control the EMT, replace host cells, remodel the ECM, regulate the immune system, act in a paracrine fashion and establish cell-cell contacts.](jcav08p0085g001){#F1}

![Normal mesenchymal stem cells (MSCs) inhibit the proliferation of leukemia MSCs. MSCs of umbilical cord blood and normal bone marrow and leukemia MSCs were isolated and cultured according to our previous report. The second passage leukemia MSCs stained with CMDil (1×104) were cultured for 24 h, then the MSCs of umbilical cord blood and bone marrow were co-cultured with the leukemia MSCs with the ratio of 1:1, 10:1 and 100:1, respectively. After five days, the numbers of leukemia MSCs were detected by flow cytometry. The inhibition rate of leukemia MSCs was calculated according to the following: inhibition rate = (numbers before co-culture - numbers after co-culture) / numbers before co-culture. The inhibition rate of the MSCs from umbilical cord blood was significantly higher than that of the MSCs from normal BM. The inhibition rate increased as the number of umbilical cord MSCs increased, but decreased as the number of BM-MSCs increased. \* p\<0.01.](jcav08p0085g002){#F2}

###### 

Comparative analysis of the anticancer effects of human tissue-derived normal MSCs *in vitro and in vivo.*

  Type of MSCs                   Tumor propagating effect                   Tumor inhibiting effect
  ------------------------------ ------------------------------------------ ------------------------------
  Bone marrow                    Acute lymphoblastic leukemia               Hepatocellular carcinoma
  Acute myeoblastic leukemia     Pancreatic cancer                          
  Chronic lymphocytic leukemia   Glioma                                     
  Lymphoma                                                                  
  Multiple myeloma                                                          
  Breast cancer                                                             
  Hepatocellular carcinoma                                                  
  Colorectal cancer                                                         
  Colon cancer                                                              
  Prostate cancer                                                           
  Renal cell carcinoma                                                      
  Endometrial tumors                                                        
  Glioma                                                                    
  Osteosarcoma                                                              
  Prostate cancer                                                           
  Ovarian cancer                                                            
  Gastric cancer                                                            
  Pancreatic cancer                                                         
  Lung cancer                                                               
  Oral tongue tumor                                                         
  Adipose tissues                Acute lymphoblastic leukemia               Murine T-cell lymphoma
  Acute promyelocytic leukemia   Multiple myeloma                           
  Chronic lymphocytic leukemia   Hepatic cancer                             
  Breast cancer                  Colorectal adenocarcinoma                  
  Lung cancer                    Prostate cancer                            
  Ovarian cancer                 Glioma                                     
  Prostate cancer                Melanoma                                   
  Kaposi sarcoma                                                            
  Melanoma tumor                                                            
  Colon cancer                                                              
  Prostate cancer                                                           
  Endometrial tumors                                                        
  Glioma                                                                    
  Head/neck cancer                                                          
  Umbilical cord/cord Blood      Acute lymphoblastic leukemia               Acute lymphoblastic leukemia
  Acute myeoblastic leukemia     Chronic myeloid leukemia in blast crisis   
  Breast cancer                  Acute myeoblastic leukemia                 
  Gastric epithelial cell        Burkitt\'s lymphoma                        
  Esophageal cancer              Multiple myeloma                           
  Mouse pancreatic cancer        Breast cancer                              
  Ovarian cancer                 Hepatic cancer                             
                                 Cholangiocarcinoma                         
                                 Bronchioloalveolar carcinoma               
                                 Prostate cancer                            
                                 Bladder tumor                              
                                 Ovarian carcinoma                          
                                 Glioma                                     
                                 Esophageal cancer                          
                                 Lung cancer                                

Note: Distinct MSCs come from different origins and exhibit a diverse range of anticancer properties. The MSCs from bone marrow and adipose tissues mainly show tumor-propagating effects; however, MSCs from umbilical cord/cord blood mainly show tumor-inhibiting effects.

###### 

Registered trials of mesenchymal stem cells (MSCs) in anticancer therapies.

  Disease                             Source of MSCs            Phase          Status               Registered ID
  ----------------------------------- ------------------------- -------------- -------------------- ---------------
  Advanced ovarian cancer             Allogeneic bone marrow    1              Not yet recruiting   NCT02530047
  Localized prostate cancer           Allogeneic bone marrow    1              Recruiting           NCT01983709
  Head and neck cancer                N/A                       1              Not yet recruiting   NCT02079324
  Recurrent ovarian cancer            Adipose tissue            1/2            Not yet recruiting   NCT02068794
  Metastatic and refractory tumors.   Autologous bone marrow    1/2            Not yet recruiting   NCT01844661
  Hematologic malignancies            Third-party bone marrow   1/2            Recruiting           NCT01092026
  Hematologic malignancies            Allogeneic bone marrow    Not provided   Recruiting           NCT02181478

Note: The trials are registered at ClinicalTrials.gov. Search performed on October 28th, 2015.
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